Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2024-08-20 Earnings Release
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
Inside Information Announcement on Preliminary Financial Data for the half year of 2024
Earnings Release Classification · 95% confidence The document is titled 'Announcement on Preliminary Financial Data for the half year of 2024' and contains summarized financial data for the half year period, including sales revenue, net profit, and asset values. It explicitly states that the data is preliminary and unaudited, and that the final detailed data will be disclosed in the 2024 interim report. The document is an announcement of preliminary financial results rather than a full interim report containing comprehensive financial statements and analysis. It is also relatively short (5349 characters) and serves to inform investors of preliminary figures and risks. According to the classification rules, such documents announcing preliminary or unaudited financial data for a period shorter than a fiscal year are best classified as Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only.
2024-08-20 English
PUBLICATION OF THE 2024 INTERIM RESULTS OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANKUANG ENERGY GROUP COMPANY LIMITED
Report Publication Announcement Classification · 95% confidence The document is an announcement by Yankuang Energy Group Company Limited regarding the publication of the 2024 interim results of its overseas subsidiary, Yancoal Australia. It summarizes key financial data for the six months ended 30 June 2024 and refers readers to the full announcement published by Yancoal Australia on the ASX and HKEX websites. The document itself is short (2892 characters) and does not contain the full interim financial report but rather a summary and a notice of publication elsewhere. According to the 'MENU VS MEAL' rule, this is an announcement about the publication of a report, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2024-08-19 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a notice announcing a forthcoming board meeting to consider the publication of the company's unaudited interim results and proposed interim dividend. It does not contain any financial data or results itself, but rather informs about the meeting where such results will be discussed. The document is short (1633 characters) and serves as an announcement rather than a report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Interim Report (IR) or Earnings Release (ER).
2024-08-16 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES APPROVAL OF MANUFACTURING LOCALIZATION REGISTRATION APPLICATION FOR AYVAKIT (AVAPRITINIB TABLETS, 100 MG) BY CHINA NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the approval of manufacturing localization registration for a drug (AYVAKIT) by the China National Medical Products Administration (NMPA). It contains no financial statements, no detailed financial performance data, no management discussion of financial results, and no regulatory certifications or officer attestations. The content focuses on regulatory approval and business updates related to drug manufacturing and market strategy. The document length is 8915 characters, which is substantial but the content is clearly an announcement of a regulatory approval event rather than a financial report or earnings release. There is no indication that this is a report publication announcement or a proxy statement. The nature of the content fits best with a Regulatory Filings (RNS) category, which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories such as earnings, capital updates, or management changes.
2024-08-15 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the Board of Directors of CStone Pharmaceuticals about a scheduled board meeting to consider and approve the unaudited interim results for the six months ended June 30, 2024, and the potential payment of an interim dividend. The document does not contain the actual interim financial results or detailed financial data but merely announces the date and agenda of the board meeting. The document length is short (1523 characters) and serves as a notification rather than a report. According to the 'Menu vs Meal' rule, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2024-08-12 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024
Major Shareholding Notification Classification · 95% confidence The document is a detailed monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for CStone Pharmaceuticals for the month ended 31 July 2024. It includes detailed tables on movements in authorized share capital, issued shares, share options, and confirmations related to compliance with listing rules. The document is not an announcement of a report but contains substantive data on share capital and share movements. It is a regulatory filing specific to share capital movements and compliance confirmations under the Exchange Listing Rules. This type of document fits best under the category of Major Shareholding Notification (MRQ) or Share Issue/Capital Change (SHA). However, since it reports on movements in securities and share capital without announcing new share issues or capital changes per se, and it is a monthly return on movements in securities, the best fit is Major Shareholding Notification (MRQ) as it relates to shareholding levels and movements. Confidence is high given the detailed share movement data and regulatory context.
2024-08-06 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.